{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:40:36Z","timestamp":1787503236510,"version":"build-2736575974"},"reference-count":52,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Myelofibrosis (MF) in the chronic phase is a challenging disease to treat, and conventional treatment options are geared toward symptom palliation. In this prospective, multicenter, phase 2 trial, 21 patients with MF (18 chronic phase, 2 accelerated phase, and 1 blast phase) were treated with a 10-day schedule of subcutaneous decitabine at 0.3\u00a0mg\/kg per day. The overall response rate was 33% (95% confidence interval, 15-57), primarily manifested as an improvement in cytopenias. The median duration of response was 7\u00a0months (range, 3-44). A high International Prognostic\u00a0Scoring\u00a0System risk score, high baseline fetal hemoglobin level, and sustained decrease in circulating CD34+ cell counts were associated with response to decitabine. All patients experienced at least 1 grade 3\/4 cytopenia. Nonhematologic toxicities were less frequent, with fatigue, anorexia, and hypocalcemia being the most common. Given the lack of effective therapies in MF with severe cytopenias, this study supports further investigation into the use of hypomethylating agents as single agents or in combination therapies. This trial was registered at www.ClinicalTrials.gov as #NCT00095784.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013215","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T15:47:51Z","timestamp":1725896871000},"page":"5735-5743","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-4232","authenticated-orcid":false,"given":"Chenyu","family":"Lin","sequence":"first","affiliation":[{"name":"1The University of Chicago Pritzker School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-8686","authenticated-orcid":false,"given":"Anand A.","family":"Patel","sequence":"additional","affiliation":[{"name":"2Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dezheng","family":"Huo","sequence":"additional","affiliation":[{"name":"3Department of Public Health Sciences, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Karrison","sequence":"additional","affiliation":[{"name":"3Department of Public Health Sciences, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-6211","authenticated-orcid":false,"given":"Koen","family":"van Besien","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Cellular Therapy, University Hospitals Cleveland Medical Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Godwin","sequence":"additional","affiliation":[{"name":"5Earle A. Chiles Research Institute, Providence Portland Cancer Institute, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorie","family":"Sher","sequence":"additional","affiliation":[{"name":"2Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howie","family":"Weiner","sequence":"additional","affiliation":[{"name":"2Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Green","sequence":"additional","affiliation":[{"name":"2Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"James L.","family":"Wade","sequence":"additional","affiliation":[{"name":"6Medical Oncology, Decatur Memorial Hospital, Decatur, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6028-7347","authenticated-orcid":false,"given":"Rebecca","family":"Klisovic","sequence":"additional","affiliation":[{"name":"7Division of Hematology & Medical Oncology, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-1348","authenticated-orcid":false,"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[{"name":"8University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-3203","authenticated-orcid":false,"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"2Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, IL"},{"name":"9The University of Chicago Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"2Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[{"name":"2Section of Hematology\/Oncology, Department of Medicine, The University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"issue":"6","key":"2024112216112610100_bib1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2024112216112610100_bib2","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"key":"2024112216112610100_bib3","volume-title":"FDA Approves Treatment for Patients With Rare Bone Marrow Disorder","year":"2019"},{"key":"2024112216112610100_bib4","volume-title":"FDA Approves Drug for Adults With Rare Form of Bone Marrow Disorder News & Events for Human Drugs","year":"2022"},{"issue":"1","key":"2024112216112610100_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"3","key":"2024112216112610100_bib6","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1158\/0008-5472.CAN-12-0735","article-title":"Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms","volume":"73","author":"Nischal","year":"2013","journal-title":"Cancer Res"},{"issue":"8","key":"2024112216112610100_bib7","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1634\/stemcells.2008-0377","article-title":"Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis","volume":"26","author":"Bogani","year":"2008","journal-title":"Stem Cell"},{"issue":"12","key":"2024112216112610100_bib8","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1182\/blood.V98.12.3249","article-title":"Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia","volume":"98","author":"Barosi","year":"2001","journal-title":"Blood"},{"issue":"10","key":"2024112216112610100_bib9","first-page":"1123","article-title":"Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders","volume":"88","author":"Passamonti","year":"2003","journal-title":"Haematologica"},{"issue":"13","key":"2024112216112610100_bib10","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/0008-5472.CAN-07-0572","article-title":"Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis","volume":"67","author":"Shi","year":"2007","journal-title":"Cancer Res"},{"issue":"19","key":"2024112216112610100_bib11","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.1158\/0008-5472.CAN-09-1823","article-title":"Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents","volume":"69","author":"Wang","year":"2009","journal-title":"Cancer Res"},{"issue":"7","key":"2024112216112610100_bib12","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood.V96.7.2379","article-title":"2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia","volume":"96","author":"Koshy","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2024112216112610100_bib13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1365-2141.2008.07027.x","article-title":"Clinical effectiveness of decitabine in severe sickle cell disease","volume":"141","author":"Saunthararajah","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"2024112216112610100_bib14","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1172\/JCI78789","article-title":"Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes","volume":"125","author":"Saunthararajah","year":"2015","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"2024112216112610100_bib15","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/bjh.16281","article-title":"Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies","volume":"188","author":"Awada","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"2024112216112610100_bib16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1046\/j.1365-2141.1999.01262.x","article-title":"The Italian Consensus Conference on diagnostic criteria for myelofibrosis with myeloid metaplasia","volume":"104","author":"Barosi","year":"1999","journal-title":"Br J Haematol"},{"issue":"2","key":"2024112216112610100_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2024112216112610100_bib18","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"2024112216112610100_bib19","author":"Cancer Therapy Evaluation Program","year":"2006"},{"issue":"1","key":"2024112216112610100_bib20","article-title":"Amplification-refractory mutation system (ARMS) analysis of point mutations","volume":"Chapter 9","author":"Little","year":"2001","journal-title":"Curr Protoc Hum Genet"},{"issue":"3","key":"2024112216112610100_bib21","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"issue":"13","key":"2024112216112610100_bib22","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2024112216112610100_bib23","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","article-title":"Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"31","author":"Mesa","year":"2007","journal-title":"Leuk Res"},{"issue":"1","key":"2024112216112610100_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000506146","article-title":"Clinical benefit derived from decitabine therapy for advanced phases of myeloproliferative neoplasms","volume":"144","author":"Zhou","year":"2021","journal-title":"Acta Haematol"},{"issue":"9","key":"2024112216112610100_bib25","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.leukres.2015.06.001","article-title":"Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic\/acute myeloid leukemia phase","volume":"39","author":"Badar","year":"2015","journal-title":"Leuk Res"},{"key":"2024112216112610100_bib26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.leukres.2018.10.001","article-title":"Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: results from a multicentre study on 284 patients","volume":"74","author":"Palandri","year":"2018","journal-title":"Leuk Res"},{"issue":"1","key":"2024112216112610100_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"5","key":"2024112216112610100_bib28","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S2352-3026(24)00067-X","article-title":"Methodological challenges in the development of endpoints for myelofibrosis clinical trials","volume":"11","author":"Barosi","year":"2024","journal-title":"Lancet Haematol"},{"issue":"13","key":"2024112216112610100_bib29","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining disease modification in myelofibrosis in the era of targeted therapy","volume":"128","author":"Pemmaraju","year":"2022","journal-title":"Cancer"},{"issue":"9","key":"2024112216112610100_bib30","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/s41375-022-01637-7","article-title":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis","volume":"36","author":"Mesa","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"2024112216112610100_bib31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"24","key":"2024112216112610100_bib32","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/bloodadvances.2018019661","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms","volume":"2","author":"Rampal","year":"2018","journal-title":"Blood Adv"},{"issue":"19","key":"2024112216112610100_bib33","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2010-03-274811","article-title":"Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)","volume":"116","author":"Thepot","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2024112216112610100_bib34","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1182\/bloodadvances.2024012880","article-title":"Treatment approach and outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era","volume":"8","author":"Patel","year":"2024","journal-title":"Blood Adv"},{"issue":"20","key":"2024112216112610100_bib35","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"2024112216112610100_bib36","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"issue":"16","key":"2024112216112610100_bib37","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","article-title":"Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine","volume":"107","author":"Blum","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"2024112216112610100_bib38","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024112216112610100_bib39","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S2352-3026(18)30182-0","article-title":"Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial","volume":"6","author":"Short","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"2024112216112610100_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JOP.18.00269","article-title":"Optimal management of neutropenic fever in patients with cancer","volume":"15","author":"Zimmer","year":"2019","journal-title":"J\u00a0Oncol Pract"},{"issue":"15","key":"2024112216112610100_bib41","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-23-0842","article-title":"A\u00a0metabolically optimized, noncytotoxic low-dose weekly decitabine\/venetoclax in MDS and AML","volume":"29","author":"Levitz","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024112216112610100_bib42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3324\/haematol.2017.187278","article-title":"Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome","volume":"104","author":"Stomper","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2024112216112610100_bib43","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1038\/bcj.2013.68","article-title":"Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"4","author":"Tan","year":"2014","journal-title":"Blood Cancer J"},{"issue":"2","key":"2024112216112610100_bib44","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jval.2020.10.017","article-title":"Patient-reported outcomes as independent prognostic factors for survival in oncology: systematic review and meta-analysis","volume":"24","author":"Efficace","year":"2021","journal-title":"Value Health"},{"issue":"12","key":"2024112216112610100_bib45","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/S1470-2045(19)30656-4","article-title":"Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review","volume":"20","author":"Mierzynska","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"2024112216112610100_bib46","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11899-017-0399-5","article-title":"Approach to MPN symptom assessment","volume":"12","author":"Geyer","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"33","key":"2024112216112610100_bib47","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"10373","key":"2024112216112610100_bib48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"issue":"suppl 2","key":"2024112216112610100_bib49","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1016\/S2152-2650(22)01456-2","article-title":"MPN-375 BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis - JAK inhibitor-na\u00efe or with suboptimal response to ruxolitinib - preliminary data from the MANIFEST Study","volume":"22","author":"Mascarenhas","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2024112216112610100_bib50","doi-asserted-by":"crossref","first-page":"9717","DOI":"10.1182\/blood-2022-167122","article-title":"A\u00a0phase 2 study of the LSD1 inhibitor bomedemstat (IMG-7289) for the treatment of advanced myelofibrosis (MF): updated results and genomic analyses","volume":"140","author":"Pettit","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2024112216112610100_bib51","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/bloodadvances.2020002929","article-title":"Cedazuridine\/decitabine: from preclinical to clinical development in myeloid malignancies","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2024112216112610100_bib52","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1016\/j.clml.2024.05.012","article-title":"Oral decitabine\/cedazuridine is an effective ambulatory therapy for patients with myelofibrosis refractory to JAK2 inhibitor therapy","volume":"24","author":"Handa","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5735\/2314899\/blooda_adv-2024-013215-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/22\/5735\/2314899\/blooda_adv-2024-013215-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:11:43Z","timestamp":1732273903000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/22\/5735\/517721\/A-multicenter-phase-2-clinical-trial-of-low-dose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":52,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,11,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013215","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}